PT  - JOURNAL ARTICLE
AU  - Huang, Zhuoying
AU  - Xu, Shuangfei
AU  - Liu, Jiechen
AU  - Wu, Linlin
AU  - Qiu, Jing
AU  - Wang, Nan
AU  - Ren, Jia
AU  - Li, Zhi
AU  - Guo, Xiang
AU  - Tao, Fangfang
AU  - Chen, Jian
AU  - Lu, Donglei
AU  - Sun, Xiaodong
AU  - Wang, Weibing
TI  - Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death
AID  - 10.1101/2022.09.04.22279587
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.04.22279587
4099  - http://medrxiv.org/content/early/2022/09/09/2022.09.04.22279587.short
4100  - http://medrxiv.org/content/early/2022/09/09/2022.09.04.22279587.full
AB  - Background Limited data are available on effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines in real-world use - especially against Omicron variants in SARS-CoV-2 infection-naïve population. During an outbreak in Shanghai’s SARS-CoV-2 infection-naïve population, we evaluated vaccine effectiveness (VE) against Omicron infection, severe or critical COVID-19, and COVID-19-related death.Methods A matched case-control study was conducted among people aged ≥3 years between 2 December 2021 through 13 May 2022. Cases were SARS-CoV-2 infected individuals, individuals with severe/critical COVID-19, or COVID-19-related deaths. Controls were selected from consecutively test negative individuals at the same time as cases were diagnosed and were exact-matched on year-of-age, gender, birthplace, illness onset date, and residency district in ratios of 1:1 with infected individuals and 4:1 with severe/critical COVID-19 and COVID-19-related deaths.Results Our study included 612597 documented SARS-CoV-2 infections, among which 1485 progressed to severe or critical illness and 568 died. Inactivated vaccine was 16.3% (95% CI: 15.4%-17.2%) effective against infection, 88.6% (95% CI: 85.8%-90.9%) effective against severe/critical COVIID-19 and 91.7% (95% CI: 86.9%-94.7%) against COVID-19 death. Ad5-vectored vaccine was 13.2% (95% CI: 10.9%-15.5%) effective against infection and 77.9% (95% CI: 15.6%-94.2%) effective against severe/critical COVIID-19. Booster vaccination with inactivated vaccines enhanced protection against severe COVID-19 (92.7%, 95% CI: 90.1%-94.6%) and COVID-19 death (95.9%, 95% CI: 91.4%-98.1%). Inactivated VE against infection began to wane 12 weeks after the last dose but two- and three-dose sustained high protection levels (>80%) against severe/critical illness and death.Conclusions Our real-world study found high and durable two- and three-dose inactivated VE against Omicron-associated severe/critical illness and death across all age groups, but lower effectiveness against Omicron infection. High direct protection from severe/fatal Omicron COVID-19 provided by inactivated vaccines, and a consequent potential reduction in health-care utilization, reinforces the critical importance of full-series vaccination and timely booster dose administration for all eligible individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Science and Technology Commission of Shanghai Municipality (Grant No. 22YJ1400200), Shanghai New Three-year Action Plan for Public Health (Grant No. GWV-10.1-XK16), Shanghai "Rising Stars of Medical Talents" Youth Development Program, Youth Medical Talents-Public Health Leadership Program (Grant No. SHWSRS (2020)_87), study on the sero-epidemiology and transmission risk of COVID-19 (Grant No. 20JC1410200), and Shanghai Municipal Science and Technology Major Project (Grant No. ZD2021CY001). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Review Committee in the Shanghai Center for Disease Control and Prevention (approval number: 2022-20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the Z.H. and X.S., upon reasonable request.VEvaccine effectivenessCIConfidence intervalRT-PCRreal time polymerase chain reactionNAATnucleic acid amplification testingRRRespiration RateNNDRSNational Notifiable Diseases Registry SystemIQRinterquartile rangesORodds ratio